Anticoagulant safe at usual dose in overweight CHD patients: study

Findings will reassure doctors that rivaroxaban is okay for patients with CHD and mild-to-moderate obesity, expert says
Reuters Health Staff writer

In overweight or obese patients with coronary heart disease, rivaroxaban at standard doses can be added to aspirin to reduce risks of MI, stroke or death, UK researchers say.

Their secondary analysis of the COMPASS trial, which compared rivaroxaban plus aspirin with aspirin alone in patients with CHD or peripheral arterial disease, assessed the safety and effectiveness of the anticoagulant in relation to BMI and body weight.